Stay updated with breaking news from Mark Mintun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON—Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening—by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after the recently…
New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study. If U.S. regulators approve, the drug would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding. Lilly's data was presented at an Alzheimer's Association internatio...
Early detection, regular monitoring are key, experts say, as new Alzheimer’s treatment options emerge
Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved…
New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months — but comes with safety risks.